Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In trading on Thursday, shares of Dr. Reddy's Laboratories Ltd. ( RDY - Get Report) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $32.90 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 65.9. A bullish investor could look at RDY's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of RDY shares: Looking at the chart above, RDY's low point in its 52 week range is $29.83 per share, with $46.95 as the 52 week high point — that compares with a last trade of $33.40. According to the ETF Finder at ETF Channel, RDY makes up 1.75% of the First Trust Chindia ETF ( FNI) which is trading lower by about 0.6% on the day Thursday.
More from Stocks
Baidu Stock Continues Bull Run as Trade Optimism, Strong Earnings Spark Surge
The Chinese tech giant is charging hard to close August, adding hope for bulls betting on an inflection point.
Jim Cramer: Hail to Estee Lauder, the New England Patriots of Retail
Under CEO Fabrizio Freda, the cosmetics giant takes risks and then does the blocking and tackling needed to win in a challenging retail environment.
This Real Estate Investment Trust Offers High Yield -- and a Solid Foundation
EPR Properties has a long, safe track record of robust growth, and a strong total return outlook.
Apple Arcade Could Be a Big Hit, But Its Value Won't Be Realized Overnight
A low price point plus one-month free trial could make Apple Arcade an appealing option for millions of gamers worldwide. But old habits could still prove hard to break.
Medtronic Rises as Heart Device Maker Pumps Out Revenue Beat
Medtronic's cardiac and vascular unit generates $2.79 billion in fiscal first-quarter revenue, surpassing analysts' estimates.